Akari Therapeutics Faces Delisting Concerns
Ticker: AKTX · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1541157
| Field | Detail |
|---|---|
| Company | Akari Therapeutics PLC (AKTX) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
Related Tickers: AKTX
TL;DR
Akari Therapeutics might be delisted - big trouble ahead.
AI Summary
Akari Therapeutics Plc filed an 8-K on November 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest event reported on November 24, 2025. The company was formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC.
Why It Matters
This filing indicates potential issues with Akari Therapeutics' continued listing on an exchange, which could significantly impact its stock price and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Celsus Therapeutics Plc (company) — Former company name
- Morria Biopharmaceuticals PLC (company) — Former company name
- November 24, 2025 (date) — Earliest event reported
- November 26, 2025 (date) — Date of report
FAQ
What specific listing rule or standard has Akari Therapeutics failed to satisfy?
The filing states a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule or standard in the provided text.
What is the earliest date associated with the reported event?
The earliest event reported is dated November 24, 2025.
When was this 8-K form filed with the SEC?
The 8-K form was filed on November 26, 2025.
What were Akari Therapeutics' previous company names?
Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC.
What is the company's primary business sector?
The company's Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 803 words · 3 min read · ~3 pages · Grade level 15.9 · Accepted 2025-11-26 17:00:46
Key Financial Figures
- $0.0001 — Market LLC Ordinary Shares, par value $0.0001 per share* N/A The Nasdaq Stock Mar
- $1.00 — ties to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810
Filing Documents
- form8-k.htm (8-K) — 43KB
- 0001493152-25-025177.txt ( ) — 248KB
- aktx-20251124.xsd (EX-101.SCH) — 4KB
- aktx-20251124_def.xml (EX-101.DEF) — 26KB
- aktx-20251124_lab.xml (EX-101.LAB) — 36KB
- aktx-20251124_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: November 26, 2025 By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: President and Chief Executive Officer